Celldex Therapeutics, Inc.
CLDX
$27.81
$1.144.27%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.45% | -5.21% | -14.24% | -11.80% | -17.52% |
| Total Depreciation and Amortization | -5.61% | 0.69% | 5.86% | 4.20% | -1.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.78% | 6.41% | 9.84% | 21.36% | 82.45% |
| Change in Net Operating Assets | 132.46% | 149.64% | -215.18% | 138.23% | -784.63% |
| Cash from Operations | -10.51% | 19.07% | -67.42% | 41.31% | -88.69% |
| Capital Expenditure | 39.56% | -174.72% | 64.95% | -38.72% | -98.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 21.17% | 17.04% | 74.23% | -48.65% | 203.99% |
| Cash from Investing | 22.06% | 16.07% | 78.61% | -49.65% | 202.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,128.57% | -68.81% | -47.67% | -68.85% | -66.62% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,128.57% | -68.81% | -47.67% | -68.85% | -66.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 119.92% | 152.66% | -39.50% | -26.86% | 91.24% |